EFFICACY OF ETANERCEPT IN TREATMENT OF VARIOUS TYPES OF JUVENILE IDIOPATHIC ARTHRITIS
نویسندگان
چکیده
منابع مشابه
Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
Methods The study included data from out-patient medical record on 69 JIA patients (45 children, 24 adults) who received ETN therapy during 2004 till 2010. Treatment efficacy was assessed using the ACR (American College of Rheumatology) Pedi 30, 50 and 70 response. Therapy was evaluated after 3, 6, 12 and 24 months (mo) of ETN treatment. Safety was assessed by recording ETN adverse events (AE)....
متن کاملThe German etanercept registry for treatment of juvenile idiopathic arthritis.
OBJECTIVE To describe a registry set up to monitor children treated with etanercept in Germany and Austria. METHODS Giannini's criteria, duration of morning stiffness, number of swollen, tender and contracted joints, adverse events, and reasons for discontinuation were assessed. RESULTS 322 patients with juvenile idiopathic arthritis (JIA) and 12 additional patients with non-JIA rheumatic d...
متن کاملEtanercept treatment in juvenile idiopathic arthritis: The Polish registry
BACKGROUND To evaluate the long-term safety and efficacy of etanercept treatment in Polish patients with juvenile idiopathic arthritis (JIA). MATERIAL/METHODS The study involved patients, fulfilling the JIA criteria of the International League of Associations of Rheumatology (ILAR), who were started on etanercept therapy after methotrexate and other synthetic disease-modifying antirheumatic d...
متن کاملEtanercept treatment for children with refractory juvenile idiopathic arthritis.
BACKGROUND Etanercept has been shown to be an effective treatment for juvenile idiopathic arthritis (JIA). In this study, we evaluated the effectiveness of etanercept therapy in the treatment of refractory JIA. METHODS This was a retrospective analysis of 11 patients with refractory JIA (polyarticular type n=7; pauciarticular type, n=2; systemic type, n=2) who received treatment with etanerce...
متن کاملChallenges in the management of juvenile idiopathic arthritis with etanercept
Biologic agents have been designed with the help of immunological studies to target particular areas of the immune system which are thought to play a role in the pathogenesis of disease. Etanercept is a soluble anti-tumor necrosis factor alpha (TNF-alpha) agent licensed for the treatment of active poly-articular juvenile idiopathic arthritis (JIA) in children aged 4 to 17 years who have failed ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current pediatrics
سال: 2013
ISSN: 1682-5535
DOI: 10.15690/vsp.v12i6.885